nvm i re-read their analysis and risk and it state:
We see Immunotherapies as the key variable in our valuation over the next 12 months. Should COR-1 (Phase II) and COR-2 (Phase Ib) both achieve positive clinical results in their current trials, and assuming no significant change in the viral shedding rate released with the COR-1 interim results, our valuation rises to 58c/share. With respect to downside risk, should both clinical programs fail, we would ascribe a zero value to Immunotherapies (at least until such time as the two HPV pre-clinical programs enter the clinic), and our valuation would fall to 39c/share.
however, the result is not negative either, so idk should i be bothered to invest here atm or not LOL
- Forums
- ASX - By Stock
- Ann: Response to Aware Query
nvm i re-read their analysis and risk and it state: We see...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.30 |
Change
-0.380(2.42%) |
Mkt cap ! $323.4M |
Open | High | Low | Value | Volume |
$15.70 | $15.94 | $15.02 | $290.0K | 18.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 280 | $15.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 779 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 280 | 15.100 |
2 | 96 | 15.020 |
1 | 15 | 15.010 |
2 | 582 | 15.000 |
1 | 1000 | 14.850 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 779 | 1 |
15.930 | 250 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
16.000 | 1250 | 2 |
Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |